After several years of garnering deals with big pharma and a successful IPO, the tides have turned for BIND therapeutics as it sheds a large portion of its workforce and cancels another trial.
The biotech announced this week that it will reduce its staff by 38% in an effort to keep its cash...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?